Single Cell Discoveries is a spin-off from the single-cell core facility at the Hubrecht Institute in Utrecht, the Netherlands. Mauro and Judith, founders of the company, have extensive experience with single-cell sequencing. Mauro worked as a PhD researcher at the Van Oudenaarden group and Judith was general manager for the single-cell core facility at the institute. Both of them have collaborated with numerous scientists from different backgrounds to set up, execute and analyse single-cell sequencing experiments.
When noticing the difficulties many researchers have with setting up single-cell sequencing experiments, they decided to join forces and incorporate Single Cell Discoveries.
Single Cell Discoveries is a one-stop-shop for single-cell sequencing as a service and is supported by the Hubrecht Institute and the Oncode Institute.
Co-founder and CEO
Mauro completed his masters in Molecular BioSciences at the University of Amsterdam and Mount Sinai hospital in New York City. He recently completed his PhD at the van Oudenaarden lab, where he worked on experimental and analytical pipelines for single-cell sequencing. Mauro will use his technical know-how and academic background in single-cell sequencing technology as CEO at Single Cell Discoveries.
Co-founder and COO
Judith completed her Masters degree in Cancer, Stem Cells and Development at Utrecht University and the van Oudenaarden lab, where she gained experience with single-cell RNA sequencing experiments and analysis. She then made the transition to managing the Hubrecht Single Cell Facility in 2016. As of June 2018, Judith will use this experience as COO at Single Cell Discoveries.
Business Development Manager
Bastiaan has a BSc degree in Biomedical Sciences and an MSc degree in Science and Business Management, both obtained at Utrecht University. Before joining Single Cell Discoveries, he worked as a consultant at Accenture (Amsterdam) and as a Sales and Marketing Manager for Cergentis (Utrecht).
Lab Manager NGS
Lotte completed her bachelors in Biomedical Sciences and her masters in Biology of Disease at Utrecht University. She will soon finish her joint PhD at the department of Medical Physiology (UMC Utrecht) and the Bakkers lab (Hubrecht), where she gained experience with genetics.
Alexander van Oudenaarden
Advisory board member
Prof. Dr. Ir. Alexander van Oudenaarden obtained his PhD in physics in 1998 from Delft University, the Netherlands. After a postdoc at Stanford, he moved to MIT in Cambridge, MA in 2000 and became Professor of Physics in 2008, as well as Professor of Biology in 2009. In 2012, he moved back to the Netherlands to become director of the Hubrecht Institute for developmental biology and stem cell research and professor of quantitative biology of gene regulation at the University Medical Center Utrecht and Utrecht University. Van Oudenaarden has been a member of the Royal Netherlands Academy of Arts and Sciences since 2014.
Advisory board member
Angus Livingstone serves as the Valorization Director for the Oncode Institute, a new Dutch foundation with the goal of bringing together the Netherlands’ top scientists in a new, world class institute that strengthens the best fundamental cancer research and drives scientific breakthrough. Oncode will accelerate the development of better cancer treatment by combining excellent research with first-class valorization in an innovative model.
Angus is excited to bring his 30 years experience at The University of British Columbia in translating academic research for social and economic benefit to the Netherlands. He has played critical roles in the creation of many Canadian technology transfer and commercialization initiatives including: entrepreneurship@UBC; The Centre for Drug Research and Development; The Alliance for the Commercialization of Canadian Technology (ACCT) Canada; Westlink Technology Commercialization Internship Program; Flintbox™; Aggregate Therapeutics IP Toolkit; West Coast Licensing Partnership; the Canada California Strategic Innovation Partnership – IP Protocol; and, UBC’s Global Access Licensing Principles.
Key support partners